Vaxcyte Finalizes $550M Common Stock Offering to Fund VAX-31 Clinical Programs

summarizeSummary

Vaxcyte, Inc. finalized its public offering of 11,000,000 shares of common stock at $50.00 per share, raising $550 million to advance its VAX-31 adult and pediatric vaccine programs and prepare for commercial launch.

check_boxKey Events

• Offering Finalized

  Vaxcyte finalized its public offering of 11,000,000 shares of common stock, with underwriters having an option to purchase an additional 1,650,000 shares.

• Capital Raised

  The offering is expected to generate $550,000,000 in gross proceeds for the company.

• Pricing Details

  Shares were offered at $50.00 per share, representing a modest discount to the last reported sale price of $52.82 on January 29, 2026.

• Strategic Use of Proceeds

  Funds will primarily support the ongoing Phase 3 clinical development of the VAX-31 adult program, the VAX-31 infant Phase 2 study, manufacturing scale-up, and pre-commercialization efforts.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms of the common stock offering, following a preliminary prospectus filed on January 29, 2026. The offering of 11,000,000 shares, with an option for underwriters to purchase an additional 1,650,000 shares, is a substantial capital raise for Vaxcyte, generating $550 million in gross proceeds. While the offering is dilutive, it is priced at a modest discount to the prior day's closing price and is crucial for funding the ongoing Phase 3 clinical development of its lead VAX-31 adult vaccine candidate (OPUS-1, OPUS-2, OPUS-3 trials), the VAX-31 infant Phase 2 study, manufacturing scale-up, and pre-commercialization activities. For a clinical-stage biotech, securing significant capital for late-stage development and commercial readiness is a critical step, albeit at the cost of shareholder dilution.